Related references
Note: Only part of the references are listed.Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates
Nikesh Kotecha et al.
CANCER CELL (2008)
Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders
Sigal Gery et al.
BLOOD (2007)
Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation
Luciana Teofili et al.
BLOOD (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia
R. A. Mesa et al.
LEUKEMIA (2006)
JAK2V617F mutation in platelets from essential thrombocythemia patients:: correlation with clinical features and analysis of STAT5 phosphorylation status
Paula G. Heller et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation
CHM Jamieson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Enhanced engraftment of hematopoietic stem/progenitor cells by the transient inhibition of an adaptor protein, Lnk
H Takizawa et al.
BLOOD (2006)
Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways
W Tong et al.
BLOOD (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis
W Tong et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Single cell profiling of potentiated phospho-protein networks in cancer cells
JM Irish et al.
CELL (2004)
Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice
L Velazquez et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Enhanced Hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk
S Takaki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Share Paper
